OH SB170

Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments (drugs, biological products, or devices) based on their genetic profile, including gene therapy and neoantigen vaccines

Requires eligible patients to have physician attestation of their condition, consideration of all FDA-approved treatments, and execution of written informed consent that discloses risks, costs, and potential outcomes including death

Protects physicians from license revocation or suspension by the State Medical Board solely for recommending individualized investigational treatments to eligible patients

Health insurers and government agencies are not required to cover costs of investigational treatments, and patients are liable for all direct expenses unless otherwise contracted with the manufacturer

Manufacturers and healthcare providers who comply with the law in good faith are shielded from private lawsuits for harm resulting from the investigational treatment